Medtronic Inc. (MDT)

[Penny Roger$]

~ Tuesday! $MDT ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $MDT ~ Earnings expected on Tuesday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=MDT&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=MDT&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=MDT
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=MDT#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=MDT+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=MDT
Finviz: http://finviz.com/quote.ashx?t=MDT
~ BusyStock: http://busystock.com/i.php?s=MDT&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=MDT >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[GrandeS]

Medtronic might want to purchase ALRT, with their new patient management platform. Makes a lot of sense with their diabetes products.

[THE GREEN EAGLE]

from yahoo news:LONDON – After Rob Summers was paralyzed below the chest in a car accident in 2006, his doctors told him he would never stand again. They were wrong.

Despite intensive physical therapy for three years, Summers' condition hadn't improved. So in 2009, doctors implanted an electrical stimulator onto the lining of his spinal cord to try waking up his damaged nervous system. Within days, Summers, 25, stood without help. Months later, he wiggled his toes, moved his knees, ankles and hips, and was able to take a few steps on a treadmill.

"It was the most incredible feeling," said Summers, of Portland, Oregon. "After not being able to move for four years, I thought things could finally change."

Still, despite his renewed optimism, Summers can't stand when he's not in a therapy session with the stimulator turned on, and he normally gets around in a wheelchair. Doctors are currently limiting his use of the device, made by Minneapolis-based Medtronic, Inc., to several hours at a time.

His case is described in a paper published Friday in the journal, Lancet. The research was paid for by the U.S. National Institutes of Health and the Christopher and Dana Reeve Foundation.

For years, certain people with incomplete spinal cord injuries, who have some control of their limbs, have experienced some improvement after experiments to electrically stimulate their muscles. But such progress had not been seen before in someone with a complete spinal cord injury.

"This is not a cure, but it could lead to improved functionality in some patients," said Gregoire Courtine, head of experimental neurorehabilitation at the University of Zurich. He was not connected to Summers' case. Courtine cautioned Summers' recovery didn't make any difference to the patient's daily life and that more research was needed to help paralyzed people regain enough mobility to make a difference in their normal routines.

The electrical stimulator surgeons implanted onto Summers' spinal cord is usually used to relieve pain and can cost up to $20,000. Summers' doctors implanted it lower than normal, onto the very bottom of his vertebrae.

"The stimulator sends a general signal to the spinal cord to walk or stand," said Dr. Susan Harkema, rehabilitation research director at the Kentucky Spinal Cord Injury Research Center in Louisville and the Lancet study's lead author.

Harkema and her colleagues were surprised Summers was able to voluntarily move his legs. "That tells us we can access the circuitry of the nervous system, which opens up a whole new avenue for us to address paralysis," Harkema said. She said prescribing drugs might also speed recovery.

Dr. John McDonald, director of the International Center for Spinal Cord Injury at Kennedy Krieger Institute in Baltimore, said the strategy could be rapidly adopted for the 10 to 15 percent of paralyzed patients who might benefit. He was not connected to the Summers case.

"There is no question we will do this for our patients," he said. McDonald added that since the electrical stimulators are already approved for pain relief, it shouldn't be difficult to also study them to help some patients regain movement.

For now, Summers does about two hours a day of physical therapy.

"My ultimate goal is to walk and run again," he said. "I believe anything is possible and that I will get out of my wheelchair one day.

[GrandeS]

watch for ALRT. they are small cap and will make a huge move on part of Medtronic business. Medtronic could take a position on them or not but whatever I expect to see a big price increase in ALRT as they receive their FDA approval

[fourkids_9pets]

medtronic ceo on latest earnings (from cnbc)

http://www.cnbc.com/id/15840232/?video=1660193762&play=1

--
4kids
all jmo

[analogdog]

FDA Approves Medtronic Drug-Coated Stent
Friday February 1, 4:56 pm ET
By Matthew Perrone, AP Business Writer
Medtronic Gets FDA Approval for Endeavor, First New Drug-Coated Stent in 4 Years

WASHINGTON (AP) -- Medtronic on Friday received federal approval to sell its drug-coated stent, the first to hit the U.S. market since safety concerns sank their popularity two years ago.

The Food and Drug Administration said it cleared the company's Endeavor stent for use in patients with clogged arteries. Medtronic said it expects to ship 100,000 units to hospitals in February.

Endeavor is one of a new generation of stents the industry hopes can rejuvenate U.S. demand for the drug-oozing devices, sales of which plummeted to $2 billion last year, down from a peak of $3.1 billion in 2005.

Stents are tiny, mesh-wire tubes that prop open arteries after they have been surgically cleared of fatty plaque. They became one of the most lucrative medical devices in modern history after companies began adding drug coatings to stents in 2003 to prevent blood clotting.

An estimated 6 million people worldwide have had one implanted.

Shares of Medtronic rose $1.35, or 2.9 percent, to $47.85 Friday.

A series of studies in 2006 showed that months after they're implanted, stent coatings have the potential to increase the risk of life-threatening blood clots unless patients continue to take anti-clotting drugs. Medical societies, such as the American College of Cardiology, urge patients to continue taking the drugs for at least a year after implantation.

In late 2006, a panel of federal advisers said that the majority of patients with the drug-coated stents have an increased risk of heart attack and death, though it's unclear whether their poor health or the drug coatings are to blame.

The percentage of stent patients receiving drug-coated versions versus the older, bare-metal models has fallen to an estimate 65 percent, from more than 80 percent, before 2006.

The new offering from Minneapolis-based Medtronic will compete with older stents from Johnson & Johnson and Boston Scientific Corp. -- two companies that cut thousands of jobs in recent months, partially because of lower stent sales.

And there's been more bad news for companies that sell stents as recently as last week. A study in the New England Journal of Medicine showed patients who underwent bypass surgery had fewer heart attacks than those who had stents implanted. The study dimmed hopes that less intrusive stenting would prove just as safe as surgery for people with clogged arteries.

Cleveland Clinic cardiologist Deepak Bhatt said it will probably be years before enough data is collected to definitively say whether one stent outperforms others.

"There's so many ways to slice and dice data that any one of these companies could probably find a way to claim superiority," said Bhatt, who directs Cleveland Clinic's cardiovascular center. "But the availability of new drug-eluting stents expands options for doctors and patients, which is always a good thing."

But not for Johnson & Johnson and Boston Scientific Inc, which account for 45 percent and 55 percent, respectively, of the U.S. market. The Endeavor is expected to capture about 20 percent of that space in 2008, according to projections from Morgan Stanley analyst Glenn Reicin.